Arginase 1 Deficiency Arg1 D clinical trials

Explore recruiting arginase 1 deficiency arg1 d clinical trials.

Also recruiting in Europe

Arginase 1 Deficiency Arg1 D trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3 Open-Label Study of Safety, Pharmacokinetics and Activity of Weekly Subcutaneous Pegzilarginase in Subjects <24 months old with Arginase 1 Deficiency

Portugal, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Arginase 1 Deficiency Arg1 D trials by city

Arginase 1 Deficiency Arg1 D in Toronto Arginase 1 Deficiency Arg1 D in Vancouver Arginase 1 Deficiency Arg1 D in Montreal Arginase 1 Deficiency Arg1 D in Calgary Arginase 1 Deficiency Arg1 D in Edmonton Arginase 1 Deficiency Arg1 D in Ottawa Arginase 1 Deficiency Arg1 D in Winnipeg Arginase 1 Deficiency Arg1 D in Quebec City Arginase 1 Deficiency Arg1 D in Hamilton Arginase 1 Deficiency Arg1 D in Kitchener Arginase 1 Deficiency Arg1 D in London Arginase 1 Deficiency Arg1 D in Halifax Arginase 1 Deficiency Arg1 D in New York Arginase 1 Deficiency Arg1 D in Los Angeles Arginase 1 Deficiency Arg1 D in Chicago Arginase 1 Deficiency Arg1 D in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease